Lemborexant, sold under the brand name Dayvigo, is an orexin antagonist medication which is used in the treatment of insomnia.[3][8] It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults.[3][8] The medication is taken by mouth.[3][8]
Side effects of lemborexant include somnolence, fatigue, headache, and abnormal dreams.[3][8] The medication is a dual orexin receptor antagonist (DORA).[3][8] It acts as a selective dual antagonist of the orexin receptors OX1 and OX2.[3][8] Lemborexant has a long elimination half-life of 17 to 55hours and a time to peak of about 1 to 3hours.[3][8] It is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action.[3][8]
Lemborexant was approved for medical use in the United States in December 2019.[9][10][11] It is a schedule IV controlled substance in the United States and may have a low potential for misuse.[3][8] Besides lemborexant, other orexin receptor antagonists including suvorexant and daridorexant have also been introduced.[12][13]
^ ab"Dayvigo". Therapeutic Goods Administration (TGA). 23 July 2021. Retrieved 5 September 2021.
^"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Retrieved 13 May 2022.
^ abcdefghijklmnopq"Dayvigo- lemborexant tablet, film coated". DailyMed. Retrieved 17 June 2021.
^"Summary Basis of Decision (SBD) for Dayvigo". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^Cite error: The named reference HoyerJacobson2018 was invoked but never defined (see the help page).
^Cite error: The named reference pmid32666570 was invoked but never defined (see the help page).
^Cite error: The named reference pmid32901578 was invoked but never defined (see the help page).
^ abcdefghiWaters K (February 2022). "Review of the Efficacy and Safety of Lemborexant, a Dual Receptor Orexin Antagonist (DORA), in the Treatment of Adults With Insomnia Disorder". The Annals of Pharmacotherapy. 56 (2): 213–221. doi:10.1177/10600280211008492. PMID 34078141. S2CID 235321467.
^"Novel Drug Approvals for 2019". U.S. Food and Drug Administration (FDA). 2 January 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
^"FDA-Approved Drugs: Lemborexant". U.S. Food and Drug Administration (FDA). Retrieved 10 January 2020.
^Cite error: The named reference Approval was invoked but never defined (see the help page).
^Cite error: The named reference pmid35043499 was invoked but never defined (see the help page).
^Markham A (April 2022). "Daridorexant: First Approval". Drugs. 82 (5): 601–607. doi:10.1007/s40265-022-01699-y. PMC 9042981. PMID 35298826.
Lemborexant, sold under the brand name Dayvigo, is an orexin antagonist medication which is used in the treatment of insomnia. It is indicated specifically...
2022, formerly under development for sleep apnea – half-life 8 hours Lemborexant (Dayvigo) – dual OX1 and OX2 antagonist – approved for insomnia in December...
formulations. Besides suvorexant, other orexin receptor antagonists like lemborexant and daridorexant have also been introduced. Suvorexant is used for the...
daridorexant, other orexin receptor antagonists, like suvorexant and lemborexant, have also been introduced. Daridorexant is indicated for the treatment...
is in contrast to other orexin receptor antagonists like suvorexant, lemborexant, and daridorexant, which are all dual orexin receptor antagonists (DORAs)...
approval the year before. The other FDA-approved orexin antagonists are lemborexant (Dayvigo) and daridorexant (Quviviq). In 2016, the University of Texas...
recently introduced class of sleep medications and include suvorexant, lemborexant, and daridorexant, all of which are FDA-approved for treatment of insomnia...
Global Information
This article incorporates text from this source, which is in the public domain.
